Evidence map›Paper›PMID 21892973›Full record

ArticleCritical care (London, England)2011

In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting.

Mehmet Birhan Yilmaz, Alexandre Mebazaa

Open access · goldAbstract readComment
In one paragraph

Article in Critical care (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Mehmet Birhan YilmazDepartment of Cardiology, Cumhuriyet University School of Medicine, Sivas, Turkey.
Alexandre Mebazaa
Assistance Publique – Hôpitaux de Paris · FRSivas Cumhuriyet Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levosimendan, in addition to its inotropic properties, could have anti-inflammatory and anti-oxidative properties, and can potentially decrease the deleterious effects of reactive oxygen species on the tissues. In their study, Hasslacher and colleagues provided not only in vitro but also in vivo evidence that levosimendan could preserve organ function in acute heart failure and septic-shock-induced myocardial depression via cooling down the oxidative burst of circulating cells.

Indexed as

Cardiotonic AgentsFemaleHeart FailureHumansHydrazonesMaleNeutrophilsPyridazinesReactive Oxygen SpeciesShock, SepticSimendanCardiotonic AgentsHydrazonesPyridazinesReactive Oxygen SpeciesSimendan

Identifiers

PMID21892973
PMCPMC3387604
OpenAlexW2143302644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.